Volume 14, Number 4—April 2008
Peer Reviewed Report Available Online Only
Conference Report on Public Health and Clinical Guidelines for Anthrax
On March 13–14, 2006, a meeting on anthrax, sponsored by the Centers for Disease Control and Prevention (CDC) in collaboration with the Southeastern Center for Emerging Biologic Threats, was held at Emory University in Atlanta, Georgia, USA. The meeting’s agenda included discussion of postexposure prophylaxis (PEP), screening and evaluation, and treatment of the various manifestations of human anthrax. The goal was to convene subject matter experts for a review of research developments and clinical experience with anthrax prophylaxis and treatment and to make consensus recommendations for updating guidelines for PEP, treatment, and clinical evaluation of patients with anthrax. A 2001 conference on guidelines for anthrax has previously been summarized in this journal (1). This article summarizes the meeting’s presentations and discussion. Consensus recommendations are summarized in the Table. Updated CDC guidelines for treatment and prophylaxis of anthrax will be published in detail in other CDC publications and are available on CDC’s website at http://www.bt.cdc.gov/agent/anthrax/index.asp.
Participants included representatives and members of academic research and clinical institutions, the Health Protection Agency of the United Kingdom, the Health Protection Agency and Armed Forces of Canada, the US Department of Defense, the US Department of Homeland Security, the US Department of Health and Human Services Office of Research and Development Coordination, the Food and Drug Administration, the National Institutes of Health, the Council of State and Territorial Epidemiologists, the American Board of Obstetricians and Gynecologists, the Infectious Diseases Society of America, and CDC (Figure). Among these participants were researchers, health department personnel, and clinicians, including the Pennsylvania pulmonologist who treated the 2006 case of inhalation anthrax (IA), the first naturally occurring case of IA in the United States since 1976 (2).
During the 2001 US outbreak of bioterrorism-related anthrax, 22 confirmed or suspected anthrax cases occurred after envelopes containing Bacillus anthracis spores in powder were sent through the mail (3). Approximately 10,000 persons were offered at least 60 days of antimicrobial PEP (4). Current CDC recommendations for PEP following potential inhalation exposure to aerosolized B. anthracis spores are 60 days of oral antimicrobial therapy in combination with a 3-dose series of anthrax vaccine adsorbed (AVA), BioThrax (BioPort Corporation, Lansing, MI, USA) administered at time zero, 2 weeks, and 4 weeks (5,6). AVA is not FDA-approved for PEP and therefore would be available under an Investigational New Drug (IND) protocol.
Antimicrobial Agent Selection
Selection of the antimicrobial agent for PEP should involve consideration of antimicrobial resistance. Variable β-lactam resistance, particularly to the cephalosporins, has been reported among naturally occurring B. anthracis isolates (7–9). β-lactamase genes have been identified in the B. anthracis chromosome (10,11), and evaluation of isolates from the 2001 event indicated the presence of both cephalosporinase and penicillinase enzymes (12). Additionally, resistance can be readily induced in vitro in B. anthracis to a variety of antimicrobial classes including fluoroquinolones, tetracyclines, macrolides, penicillins, and other β-lactams (8,13–16).
Ciprofloxacin, doxycycline, and penicillin G procaine have demonstrated efficacy for PEP in a nonhuman primate model (17) and are FDA-approved for “inhalational anthrax (postexposure)” in all age groups (18). Meeting participants reiterated existing CDC recommendations for ciprofloxacin and doxycycline as equivalent first-line antimicrobial agents for PEP, as they are equally efficacious for PEP and have similar susceptibility profiles among naturally occurring isolates (9,17). Both have similar safety profiles, with a low rate of anaphylactic reactions (19,20). Following the bioterrorism event of 2001, there were no differences in self-reported symptoms with use of either drug for PEP, and no serious adverse events could be definitely related to their use (21).
Levofloxacin is FDA-approved for “inhalational anthrax (postexposure)” in adults 18 years of age and older (22). There are safety data for up to 28 days of use, but safety data on extended use up to 60 days are limited (22). Therefore, levofloxacin is recommended as a second-line PEP antimicrobial agent, to be reserved for instances where medical issues may call for its use.
Penicillins should not be initially used for PEP of anthrax, due to concern for penicillin resistance, which has been found in naturally occurring isolates, and because of the low concentrations achieved with oral penicillins in pulmonary secretions, tissue, and within alveolar macrophages (23,24). Amoxicillin can be used for PEP once the B. anthracis strain has been proven penicillin susceptible, when other antimicrobial agents are not considered safe to use, such as for pediatric patients and for nursing or pregnant women. However, amoxicillin is not FDA-approved for this indication, and this use is considered “off-label.” Therefore, amoxicillin use for PEP in a mass-exposure event might be provided under an IND or under an Emergency Use Authorization in a declared emergency. Amoxicillin use for PEP is discussed further in the section below on special populations. Other antimicrobial agents, including clindamycin, chloramphenicol, rifampin, vancomycin, and other fluoroquinolones, may be considered for off-label use in patients unable to tolerate FDA-approved antimicrobial agents for PEP.
Duration of Prophylaxis Regimen
The PEP antimicrobial regimen should remain for 60 days, combined with 3 doses of AVA. This duration is supported by data from the 1979 Sverdlovsk anthrax outbreak (25): illness up to 58 days following inhalation exposure to anthrax in nonhuman primates receiving antibiotics alone for 30 days (17), and demonstrated efficacy of the PEP combination of antimicrobial therapy and vaccination with AVA (17).
Participants discussed whether a shortened course of antimicrobial therapy plus a 3-dose AVA series would be effective, based on recent nonhuman primate research of a successful 14-day PEP course of ciprofloxacin combined with 3 AVA doses, and demonstrated immune response to AVA (26), and on evidence of seroconversion among clinical trial participants following 3 doses of AVA (27). However, there are no well-defined serologic correlates of protection to demonstrate that AVA vaccination has conferred adequate protective immunity in a person receiving PEP. Additionally, there are no human clinical trial data supporting any reduction in the duration of antimicrobial PEP, and there are isolated AVA study participants who have failed to seroconvert following vaccination (CDC, unpub. data). Therefore, it was deemed prudent to maintain the recommended 60-day course of antimicrobial therapy combined with the 3-dose AVA series to ensure adequate protection for all persons requiring PEP after aerosolized B. anthracis exposure.
Since 2001, when CDC guidelines for the clinical evaluation of patients with possible IA in the event of possible mass exposure were published in the MMWR (28), several alternative screening algorithms have been suggested including the Inova Fairfax protocol proposed by Mayer et al (29), and the 3-tier screening protocol from Hupert et al (30).
The goal of all IA screening algorithms should be to evaluate large numbers of patients seeking treatment in emergency departments and identify potential IA cases: 1) during a potential or confirmed mass event; 2) when there is a known threat or epidemiologic data suggesting an increased risk for anthrax; or 3) when there is clinical suspicion of anthrax based on symptoms consistent with IA, including fever and persistent tachycardia, among others (28,29). The low sensitivity and specificity of such screening algorithms may not detect an isolated IA case; therefore, these algorithms are not meant to serve as general guidance for identifying IA without appropriate epidemiologic or clinical data. For example, neither the original CDC guidelines nor the proposed Inova Fairfax guidelines would have detected the solitary 2006 IA case (2). Nor should IA screening algorithms replace existing emergency department (ED) screening guidelines for patients with symptoms of community-acquired pneumonia (CAP); routine CAP cases are likely to be selected as potential IA cases when using these algorithms; additional diagnostics will be required to rule out IA.
Mayer et al retrospectively evaluated CDC’s screening guidelines, using the 11 IA cases from 2001 included among an ED patient population from the same period. On the basis of their analysis, they proposed revised screening guidelines. CDC guidelines successfully identified only 1 of the 11 cases, whereas the Inova Fairfax algorithm modified from CDC guidelines successfully identified 9 of the 11 cases (29). Participants debated whether the recommendation to reduce the number of clinical symptoms required by the Inova Fairfax guidelines warranted further evaluation (Table) because IA case-patients who seek treatment early in the course of the disease could be missed as they may not yet have all of the required symptoms. Including fever and tachycardia as necessary symptoms to begin the algorithm, timing public health notification, and reducing the stringency of the requirement for an epidemiologic link were discussed. Participants agreed that elements of the Inova Fairfax protocol should be incorporated into future CDC-recommended screening algorithms. They further recommended that validation studies be conducted and feedback collected to determine the accuracy and effectiveness of the algorithm in identifying cases of IA in an outbreak setting.
Hupert et al proposed a 3-tier screening protocol to identify potential early IA case-patients in the setting of a large-scale anthrax exposure, to aid ED physicians in decisions regarding PEP, and to support the clinical treatment decision process (30). Participants agreed that such a large-scale screening algorithm for persons with potential aerosol exposure to anthrax in a mass exposure setting should be addressed in CDC’s guidelines; however, such an algorithm was not adequately validated for adoption as a CDC recommendation.
Clinicians considering IA as a differential diagnosis should alert hospital microbiology staff of their suspicions and obtain blood cultures as early as possible before antimicrobial treatment. Gram-stain analyses of blood samples have previously detected bacteremia in systemic anthrax cases and in animal models (31,32) and may be informative.
Thoracic imaging remains a critical tool for the diagnosis of IA. Thoracic imaging studies were abnormal in all 11 of the IA cases from 2001 (8/11 with widened mediastinum, 9/11 with pleural effusions, and 7/11 with pulmonary infiltrates). However, initial ED thoracic radiographs may not reveal the classic widened mediastinum described for IA in all cases (33,34). In severe IA cases, thoracic computerized tomography without contrast was suggested as having utility for viewing hemorrhagic mediastinal lymph nodes.
Sensitivity and specificity analyses were recommended for evaluating any proposed IA screening algorithms, using historical IA cases incorporated into ED populations from annual influenza seasons or other periods with increased numbers of respiratory illness cases. Neither current CDC nor proposed alternative guidelines are applicable for pediatric patients because of lack of data on pediatric IA cases. Participants called for development of screening guidelines for children in collaboration with the American Association of Pediatrics and other pediatric care partners.
Treatment of Severe Disease, including Inhalation and Gastrointestinal Anthrax, Anthrax Meningitis, and Bacteremia
Current CDC recommendations for the treatment of anthrax were published in October 2001 specifically for cases resulting from the 2001 anthrax bioterrorist attack. After presentations on the clinical course of IA cases from 2001 and 2006 and discussion of the limited treatment success of IA cases from 2001 (5/11 patients died despite aggressive therapy), participants recommended revision of CDC treatment protocols for IA and serious systemic illness from anthrax.
Clinical or subclinical meningitis in patients with IA is likely. Meningitis is reported with all 3 clinical forms of anthrax and likely results from hematogenous spread across the blood-brain barrier when bacteremia is present. During the 2001 outbreak, although only 1 of the 11 IA case-patients had meningitis, 4 others had symptoms suggesting meningeal involvement. Confirmation of meningitis was not obtained in these 4 case-patients, and cerebrospinal fluid was not examined in all patients. If these 4 case-patients did have subclinical or early meningitis, then 45% of the 2001 IA case-patients had meningeal involvement (33). Additionally, hemorrhagic leptomeningitis was reported from autopsies in 21 (50%) of 42 IA fatalities from the 1979 Sverdlovsk outbreak (35); meningoencephalitis was reported in 44% of fatal cases in a review of 82 IA cases from 1900 to 2005 (including the 11 bioterrorism (BT)-related cases from 2001) (34). Furthermore, IA studies of nonhuman primates have demonstrated meningeal involvement in up to 77% of experimental animal cases (32). Therefore, meningeal involvement should be suspected in IA or other cases of systemic anthrax.
For treatment of anthrax cases with severe systemic or life-threatening disease (including IA and gastrointestinal anthrax), and for cases with fulminant bacteremia, IV ciprofloxacin is recommended over doxycycline as the primary antimicrobial agent unless ciprofloxacin use is contraindicated (fluoroquinolones are bactericidal while tetracyclines are bacteriostatic). Additionally, because meningeal involvement is likely in systemic anthrax cases, ciprofloxacin is theoretically favored over doxycycline; central nervous system (CNS) penetration of ciprofloxacin in the presence of meningeal inflammation is much higher than the poor CNS penetration of doxycycline (31). Although ciprofloxacin is the only fluoroquinolone for which data are available, other fluoroquinolones with similar spectrums of activity and CNS penetration may also be appropriate.
At least 1 or more additional agents with adequate CNS penetration and in vitro activity against B. anthracis (e.g., ampicillin or penicillin, meropenem, rifampin, or vancomycin) should be used in the treatment of systemic cases of anthrax regardless of clinical suspicion of meningeal involvement. Clindamycin is strongly recommended for inclusion in the antimicrobial regimen because of its ability to inhibit protein synthesis, which may reduce exotoxin production. Participants recommended continuing the current 60-day course of antimicrobial therapy, with adjustment of the regimen based on the clinical course of the disease in the patient (36). The use of corticosteroids as an adjunct to antimicrobial therapy may benefit patients with anthrax meningitis (31); however, with no efficacy data from controlled clinical trials, this adjunctive treatment may be of no benefit for toxin-mediated tissue edema.
Early and aggressive pleural fluid drainage is recommended for all IA case-patients and is consistent with the standard of care for empyema or complicated pneumonia. This recommendation is based on the experience that chest tubes or early serial drainage of pleural effusions seemed to be beneficial in the successful clinical therapy of the surviving IA patients in 2001 and in the recent 2006 IA case (2,33). Evaluation of the treatment of IA cases from 1900 to 2005 showed pleural fluid drainage to be significantly associated with decreased mortality (34). Analysis of serial pleural fluid samples from the 2006 IA case showed high pleural fluid lethal toxin levels. The positive outcome of this case likely resulted from a combination of the mechanical effects on respiration from fluid drainage and the reduction in lethal toxin levels by removing pleural effusions (2).
Treatment with oral ciprofloxacin or doxycycline for 7–10 days is recommended for localized or uncomplicated cases of naturally acquired cutaneous anthrax, such as that associated with exposure to animals with anthrax, or to products such as hides from animals with anthrax. If susceptibility testing is supportive, oral therapy with penicillin V or amoxicillin may be used to complete the course of treatment. For severe cases of naturally acquired cutaneous anthrax with signs of systemic involvement, extensive edema, or lesions of the head and neck, IV therapy for 7–10 days using ciprofloxacin or doxycycline is preferred; IV penicillin G, if supported by susceptibility testing, may be used to finish the 7- to 10-day course. It was considered widely accepted knowledge that penicillin is very effective against B. anthracis, can render cutaneous lesions culture-negative within 24 hours, and has long been the treatment of choice in many parts of the world. Therefore, despite reports of penicillin-resistant isolates and the potential for inducible beta-lactamases, participants agreed that 7–10 days of penicillin is usually sufficient for treatment of uncomplicated naturally acquired cutaneous anthrax. However, adequate dosages of penicillins must be used, patients must be monitored for clinical response, and susceptibility testing must be conducted to confirm the appropriateness of the antimicrobial choice. Other fluoroquinolones such as levofloxacin are recommended as additional options for antimicrobial treatment of naturally acquired cutaneous anthrax.
For bioterrorism (BT)-related cutaneous anthrax, any patient is at risk for IA because of potential aerosol exposure; the duration of antimicrobial therapy should remain 60 days to provide a full course of PEP. For localized or uncomplicated cases of BT-related cutaneous anthrax, oral ciprofloxacin or doxycycline is recommended. Patients with BT-related cutaneous anthrax with signs of systemic involvement, extensive edema, or lesions of the head or neck should be treated with IV ciprofloxacin using a multidrug approach, as previously described for IA and severe disease. Patients may be switched to oral therapy when clinically appropriate to complete the 60-day regimen; in uncomplicated cases amoxicillin may be used to complete the regimen if the B. anthracis strain is proven susceptible (36).
There is insufficient evidence to conclude that the immune response to cutaneous anthrax is sufficient to justify shortening the 60-day duration of antimicrobial therapy. However, severe local reactions to anthrax vaccine were reported in 2 vaccine recipients with a previous history of cutaneous anthrax during a trial of an earlier protective antigen-based anthrax vaccine (37). For BT-related cutaneous anthrax in patients without a prior history of cutaneous disease, the recommended regimen should remain 60 days of antimicrobial therapy plus 3 doses of AVA; for BT-related cutaneous anthrax in patients with a previous history of cutaneous disease, 60 days of antimicrobial therapy is recommended but vaccine should not be used because of the risk of adverse events (37).
Immune globulin of animal origin has been used with some success in the treatment of human anthrax for many years (34,38), and human-derived anthrax immune globulin (AIG) was part of the successful treatment of the 2006 IA case-patient under an emergency IND protocol. (2). Although participants agreed that clinical data are insufficient to develop general recommendations for the use of AIG and other targeted immunotherapeutics for the treatment of severe anthrax, they did recommend that CDC continue to offer AIG under emergency IND on a patient-by-patient basis.
Timing of immune globulin administration is critically important given the small window in which AIG can be effective as anthrax toxins bind and move intracellularly quickly; early administration to prevent toxin binding was stressed. However, data on the optimal timing to initiate immune therapy are lacking. Immunotherapeutics should continue to be considered for patients with severe systemic illness, for example in patients with evidence of organ dysfunction in >2 organ systems or lack of clinical response to standard therapy. A high research priority should be to continue to evaluate immunotherapeutics as they are developed for inclusion in future recommendations.
Treatment of anthrax during pregnancy should remain the same as for adults because of the severity of the disease. Ciprofloxacin is recommended as the first-line oral antimicrobial agent for PEP or treatment of anthrax during pregnancy (39). Doxycycline should not be used for PEP or treatment during pregnancy unless started in the third trimester. Transition to amoxicillin for PEP remains recommended when the isolate involved is susceptible to penicillin.
Although the Department of Defense has published safety data on AVA during pregnancy (40), the statistical power of the study was limited. Meeting participants indicated that additional safety data are needed to support appropriate decisions regarding recommendations for this population. It was proposed that AVA be included in the PEP protocol for pregnancy if there is strong evidence of risk for IA or if the benefit outweighs risks from vaccination. Vaccination may also be deferred to immediately postpartum if the risk of IA persists because of limited safety data on AVA use during pregnancy.
For breastfeeding mothers, if the infant was also exposed, the mother’s antimicrobial regimen should match the child’s regimen when possible. When not possible, the mother can pump and discard her breast milk while being treated, and resume breastfeeding after completing her course of PEP.
Recommendations for treatment of BT-related anthrax in pediatric patients should be consistent with adult antimicrobial agents, with ciprofloxacin favored for severe disease. Ciprofloxacin or doxycycline is recommended as the first-line oral antimicrobial agent for PEP. Amoxicillin is recommended as an alternative in pediatric treatment when the isolate involved is susceptible to penicillin. Participants discussed the need to determine the appropriate amoxicillin PEP dose for pediatric patients to resolve differences between CDC and FDA recommendations. The consensus was that the amoxicillin PEP dose should err on the higher end in favor of ensuring efficacy. Data are lacking on the safety of long-term use of high-dosage amoxicillin in pediatric patients; participants recommended additional research and Pediatric Advisory Committee input to determine the most appropriate pediatric amoxicillin PEP dosage. Currently, anthrax vaccination cannot be recommended for use in children because safety and efficacy data are lacking.
Finally, for special populations such as geriatric patients or patients with special medical conditions, standard medical practice should prevail. Physicians should perform standard medical screening for potential drug interactions and for underlying diseases such as renal failure before initiating treatment or PEP; drug selection and dosage should be adjusted accordingly.
Research into the evaluation, prevention, and therapy of anthrax is ongoing, and CDC guidelines for anthrax are subject to change based on new information and expert recommendation. When available, updated CDC guidelines for treatment and prophylaxis of anthrax will be published in detail in other CDC publications.
Dr Stern, a member of CDC’s Epidemic Intelligence Service at CDC from 2005–2007, has conducted medical research in numerous foreign countries, including Cuba, Peru, and Vietnam, and served as an Albert Schweitzer fellow in pediatrics in Lambarene, Gabon. He is currently completing a pediatric infectious diseases fellowship at Children’s Hospital San Diego.
We thank the meeting’s scientific chair panel: Arthur Friedlander, Brad Leissa, David Stephens, Mary Wright, and Ivy Adekoya, as well as Antoinette Seright for organizational contributions.
Luciana Borio, University of Pittsburgh Medical Center; Phil Brachman, Emory University; Eddy Bresnitz, NJ Department of Health and Senior Services/Council of State and Territorial Epidemiologists (DHSS/ CSTE); Jeff Brady, Drusilla Burns, Cynthia Kelley, Eileen Navarro-Almario, Roxanne G. Shively, US Food and Drug Administration/Center for Biologics Evaluation and Research (FDA/CBER); Dan Hanfling, Thom A. Mayer, Inova Fairfax Hospital; Phil Hanna, University of Michigan College of Medicine; Scott A. Harper, NYC Department of Health and Mental Hygiene (DHMH); Nathaniel Hupert, Weill Medical College, Cornell University; Dan Lucey, Washington Institute/Institute for Defense Studies and Analyses (IDSA); Lt Col H.C. MacKay MD MHSc, Department of National Defense of Canada; Mark Martens, Gilles Monif, University of Oklahoma; Robert C Spencer, Health Protection Agency, UK; Peter Turnbull, Porton Down, UK; Peter Uhthoff, Office of Public Health Security of Canada; James Walsh, Guthrie–Robert Packer Hospital, Sayre, PA; John Carney, Noreen Hynes, US Department of Health and Human Services (DHHS); COL Steve Ford, COL John Grabenstein, US Department of Defense, Office of the Surgeon General (DOD/OTSG); Ed Nuzum, US National Institutes of Health (NIH); Segaran Pilai, US Department of Homeland Security (DHS); and Clare Dykewicz, Arnold Kaufmann, Nina Marano, Ken Martinez, Conrad Quinn, Nicki Pesik, Nancy R. Messonnier, Lisa Rotz, Sean Shadomy, Dan Sosin, Eric Stern, Fred Tenover, Tracee Treadwell, Kristin Uhde, and Patty Wilkins, US Centers for Disease Control and Prevention (CDC).
- Bell DM, Kozarsky PE, Stephens DS. Conference Summary: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222–5.
- Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44:968–71.
- Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Resnitz EA, Butler JC, Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019–28.
- Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124–32.
- CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2002;51:1024–6.
- Centers for Disease Control and Prevention. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace. MMWR Morb Mortal Wkly Rep. 2004;53(RR07):1–12.
- Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis. 1991;23:333–5.
- Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull. 1990;68(Suppl):95–8.
- Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol. 2004;42:3626–34.
- Chen Y, Succi J, Tenover FC, Koehler TM. ß-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J Bacteriol. 2003;185:823–30.
- Materon IC, Queenan AM, Koehler TM, Bush K, Palzkill T. Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrob Agents Chemother. 2003;47:2040–2.
- Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909–19.
- Athamna A, Athamna M, Abu-Rashed N, Medlej B, Bast DJ, Rubinstein E. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother. 2004;54:424–8.
- Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother. 2003;47:2362–5.
- Choe CH, Bouhaouala SS, Brook I, Elliot TB, Knudson GB. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother. 2000;44:1766.
- Brook I, Elliott TB, Pryor HI, Sautter TE, Gnade BT, Thaker JH, In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001;18:559–62.
- Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Postexposure prophylaxis against experimental inhalation anthrax. [s]. J Infect Dis. 1993;167:1239–43.
- Department of Health and Human Services. Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). Fed Regist. 2001;66:55679–82.
- Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment wth ciprofloxacin. Ann Intern Med. 1989;111:1041–3.
- Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol. 1997;133:1224–30.
- Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Serious adverse events among participants in the Centers for Disease Control and Prevention's anthrax vaccine and antimicrobial availability program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis. 2003;37:905–11.
- Ortho-McNeil Pharmaceutical. Product insert, Levaquin (Levofloxacin) tablets, 2004.
- Weingartner L, Sitka U, Patsch R, Thiemann HH, Bromme W, Richter I. Amoxicillin in paediatrics, with special reference to its excretion into bronchial secretion. Int J Clin Pharmacol Ther Toxicol. 1980;18:185–9.
- Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax. 1994;49:1134–8.
- Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202–8.
- Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A. 2006;103:7813–6.
- Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006;24:3654–60.
- Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:941–8.
- Mayer TA, Morrison A, Bersoff-Matcha S, Druckenbrod G, Murphy C, Howell J, Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001? Clin Infect Dis. 2003;36:1275–83.
- Hupert N, Bearman G, Mushlin A, Callahan M. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139:337–45.
- Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis. 2005;5:287–95.
- Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73:691–702.
- Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933–44.
- Holty JE, Bravata DM, Liu HRAO. K.M. M, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006;144:270–80.
- Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90:2291–4.
- Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909–19.
- Brachman P, Gold H, Plotkin S, Fekety F, Werrin M, Ingraham N. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:632–45.
- Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med. 1986;151:71–7.
- Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99:366–8.
- Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA. 2002;287:1556–60.
Suggested citation for this article: Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis [serial on the Internet]. 2008 Apr [date cited]. Available from http://www.cdc.gov/EID/content/14/4/e1.htm